Analyst Ratings for Rocket Pharmaceuticals (RCKT)
RCKT Rating Summary
RCKT Price Target Summary
- Highest: $15.00 (Cantor Fitzgerald)
- Lowest: $3.00 (Goldman Sachs)
- Average: $9.17
* Over Last 12-Mos
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$9.17 (+146.4%)
* Over Last 12-Mos
Rating Score: 6 / 10
Percentile Rank: 63%
Avg. $ Target:
$9.17 (+146.4%)
* Over Last 12-Mos
Rating Score: 6 / 10
Percentile Rank: 63%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/1/2026 | Chardan | Keay Nakae | New Coverage | Buy (N/A) |
11.00 (N/A) |
3.72 (3.72) |
0% | Details |
| 12/19/2025 | TD Cowen » Updated 8/3/2026 |
Tara Bancroft | New Coverage | Hold (N/A) |
N/A (N/A) |
3.27 (3.72) |
13.76% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
